Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Breast Cancer treatment details. Chemotherapy. Université Libre de Bruxelles, Brussels, Belgium

Survival: 11.9 months
Toxicity Grade: 4
Treatments: Chemotherapy
Country: Belgium
City/State/Province: Brussels
Hospital: Université Libre de Bruxelles
Journal: Link
Date: 4/2014

This phase 2 study involved female advanced triple-negative breast cancer (TNBC) patients who were divided into three separate treatment groups. Group A consisted of 55 patients with a median age of 53 years. Group B consisted of 57 patients with a median age of 51 years. Group C consisted of 28 patients with a median age of 50.5 years.

Patients in group A received chemotherapy with paclitaxel and a special formulation of paclitaxel called EndoTAG-1, in which the drug is embedded in liposomal membranes targeting tumor endothelial cells.

Patients in group B were administered chemotherapy with EndoTAG-1 only.

Patients in group C were administered chemotherapy with paclitaxel only.

There were two adverse event-related deaths in group A due to unspecified causes that were not believed to be treatment-related. Grade 3-4 neutropenia and fatigue were also reported.

The most severe toxicities in group B were of grade 4 and included grade 3-4 respiratory disorders and fatigue.

There was one adverse event-related death in group C due to an unspecified cause that was not believed to be treatment-related. Grade 3-4 neutropenia and anemia were also reported.

The median overall survival rates for groups A, B, and C were 13.0, 11.9, and 13.1 months, respectively.

This study was supported by Medigene AG, makers of EndoTAG-1.

Correspondence: Dr. Ahmad Awada; email:

E-mail to a Friend Email Physician More Information